Most people with Medicaid coverage pay $0 for the full course of EPCLUSA or its Authorized Generic¹

SUPPORT ACCESS DURING THEIR TREATMENT JOURNEYS

ONLY EPCLUSA AND SOFOSBUVIR/VELPATASVIR, ITS AUTHORIZED GENERIC, PROVIDE 94% OF ALL PATIENTS ACCESS TO TREATMENT NATIONALLY (VS 68% FOR MAVYRET^®)²

Placement on the formulary is not intended to imply any claims regarding safety, efficacy, or comparability of products.

Based on national coverage (Exclusive or Preferred) lives as of June 2024. Local coverage may differ.²

Exclusive = is on formulary while other DAAs are not, has a lower tier status than other DAAs, or is required in a step therapy process vs other DAAs.

Preferred = shares the lowest tier status with at least one DAA.

Access support throughout treatment journeys

Support Path^® can do a benefits investigation and provide information about:

Coverage support information for patients regardless of insurance
Prior authorization

The Patient Assistance Program for eligible uninsured patients

Talk with Support Path
(Monday-Friday, 9AM-8PM ET),
or visit the website:

1-855-7-MYPATH
(1-855-769-7284)

MySupportPath.com

INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

Important Safety Information

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Warnings and Precautions

Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/ or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir- containing regimen. In patients without alternative viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.

Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Strong Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.

Adverse Reactions

The most common adverse reactions (≥10%, all grades) with EPCLUSA in adults and pediatric patients 6 years of age and older were headache and fatigue. The most common adverse reactions (≥10%, grade 1 or 2) for pediatric patients less than 6 years of age were vomiting and spitting up the drug.

Drug Interactions

Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.

Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.

Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.

Please see full Prescribing Information for EPCLUSA, including BOXED WARNING on hepatitis B reactivation.

SUPPORT ACCESS DURING THEIR TREATMENT JOURNEYS

ONLY EPCLUSA AND SOFOSBUVIR/VELPATASVIR, ITS AUTHORIZED GENERIC, PROVIDE 94% OF ALL PATIENTS ACCESS TO TREATMENT NATIONALLY (VS 68% FOR MAVYRET®)2

Access support throughout treatment journeys

Support Path® can do a benefits investigation and provide information about:

ONLY EPCLUSA AND SOFOSBUVIR/VELPATASVIR, ITS AUTHORIZED GENERIC, PROVIDE 94% OF ALL PATIENTS ACCESS TO TREATMENT NATIONALLY (VS 68% FOR MAVYRET^®)²

Support Path^® can do a benefits investigation and provide information about: